Makis W et al., 2025-05-26: Three-patient case series of self-administered fenbendazole in advanced cancer, published in May 2025 and retracted in January 2026. The patients took 222 mg/day (one patient 222-444 mg/day) alongside conventional treatment and many supplements; the paper reports tumour regression on scans and falling markers.
On November 22, 2021, she began self-administering FBZ daily at a dose of 222 mg. In December 2021, she received fulvestrant injections (an estrogen receptor blocker) intended to inhibit cancer growth in a manner similar to restricting glucose.
case 1 (Results)
Makis W et al., 2025-05-26: Three-patient case series of self-administered fenbendazole in advanced cancer, published in May 2025 and retracted in January 2026. The patients took 222 mg/day (one patient 222-444 mg/day) alongside conventional treatment and many supplements; the paper reports tumour regression on scans and falling markers. Patient-reported, not independently verified. Study type: case series (retrospective; self-administration). N=3. Country: authors in Canada (Cross Cancer Institute, Edmonton), Canada (International Society for Orthomolecular Medicine) and France (Association Cancer et Metabolisme); patients' country not stated in the text read. Doses as published: patient 1 – 222 mg/day for 8 months from 2021-11-22, plus fulvestrant and targeted radiation; patient 2 – 222-444 mg/day from December 2021, plus vitamin D/K2/magnesium, melatonin 10-40 mg/day, berberine, curcumin, artemisinin, cimetidine. Route: oral. Funder: 'No funding was received.' Declared conflicts: 'Authors state no conflict of interest' – which is precisely what the retraction later disputed. Comparator: none; each patient served as their own historical control and received concurrent conventional therapy, so attribution to fenbendazole is not possible from the paper. RETRACTED 2026-01-21 (see FBB-31). Pagination check: the retraction notice cites 18:856-863 (matching the prompt's citation) while the PMC article page displays 18(1):864-871. Also filed as FBA-50, FBD-05, FBA-60, FBA-32, FBE-37, FBA-28 (claims C10, C2, C4, C5, C6, F1). Study type: uncontrolled series.
